Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment by Caporali, R, Aletaha, D, Sanmarti, R, Takeuchi, T, Mo, D, Haladyj, E, Zaremba-Pechmann, L, Taylor, PC

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis by Taylor, P, Blanco, R, Ikeda, K, Jia, B, Chen, YF, Walls, C, Haladyj, E, Fautrel, B

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19 by Bieber, T, Feist, E, Irvine, AD, Harigai, M, Haladyj, E, Ball, S, Deberdt, W, Issa, M, Grond, S, Taylor, PC

Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications by Taylor, PC, Bieber, T, Alten, R, Witte, T, Galloway, J, Deberdt, W, Issa, M, Haladyj, E, De La Torre, I, Grond, S, Wollenberg, A

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience by Taylor, PC, Laedermann, C, Alten, R, Feist, E, Choy, E, Haladyj, E, De La Torre, I, Richette, P, Finckh, A, Tanaka, Y

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study by Caporali, R, Taylor, PC, Aletaha, D, Sanmartí, R, Takeuchi, T, Mo, D, Haladyj, E, Bello, N, Zaremba-Pechmann, L, Fang, Y, Dougados, M